Bexion Pharmaceuticals, Inc. Announces the Opening of a Pediatric Phase I Safety Study Using BXQ-350 in the Treatment of Rare CNS and Solid Tumors
FOR IMMEDIATE RELEASE Covington, KY ~ April 18, 2019 Bexion Pharmaceuticals, Inc., a clinical stage oncology company, announced today the initiation of an open-label Phase 1 Safety Study of BXQ-350. The first US site is [...]
FOR IMMEDIATE RELEASE Covington, KY ~ April 2, 2019 Bexion Pharmaceuticals, Inc. (Bexion) announced today that the company has assembled a Clinical Advisory Board (CAB). The CAB is comprised of Key Opinion Leaders (KOLs) in [...]
Bexion Pharmaceuticals Announces the Opening of Phase I Part 3 FOR IMMEDIATE RELEASE Covington, KY ~ February 22, 2019 - Bexion Pharmaceuticals, Inc. (Bexion) announced today the opening of Part 3 of their Phase I First-In-Human [...]
Bexion Pharmaceuticals is developing innovative cures for cancer.
Unlike any other potential drug known in development, BXQ-350 has an entirely new and novel mechanism of action.
In July 2016 Bexion received a “Study May Proceed” letter from the FDA, allowing Bexion to initiate the first clincial trial using BXQ-350 to dose patients with cancer (solid tumors and glioblastoma).
Information about the Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors trial can be found at https://www.clinicaltrials.gov/show/NCT02859857